Results 61 to 70 of about 9,435,635 (153)
Modified Adeno-associated virus (AAV) particles for gene therapy
The present invention relates to improved adeno-associated virus (AAV) particles for gene delivery and gene therapy. Provided are adeno associated virus (AAV) particles that comprise a modified capsid. The present invention further relates to methods for
Heppenstall, P. +3 more
core +1 more source
Association between adeno‐associated virus genomic titers and intracellular plasmid levels
The recombinant adeno‐associated viral (rAAV) vector is one of the most effective viral vectors in gene therapy because of its low immunogenicity, high transduction efficiency, broad tissue specificity, and long‐term transgene expression ability. HEK293T
Kyoko Masumi‐Koizumi +4 more
doaj +1 more source
Onset of experimental severe cardiac fibrosis is mediated by overexpression of angiotensin-converting enzyme 2 [PDF]
Angiotensin-converting enzyme (ACE) 2 is a recently identified homologue of ACE. There is great interest in the therapeutic benefit for ACE2 overexpression in the heart.
Smith, Godfrey +12 more
core +1 more source
Recombinant adeno-associated viruses (rAAVs) are the predominant gene therapy vector. Several rAAV vectored therapies have achieved regulatory approval, but production of sufficient rAAV quantities remains difficult.
Nina K Jain +2 more
doaj +1 more source
Capsid-specific removal of circulating antibodies to adeno-associated virus vectors
International audienceNeutralizing antibodies directed against adeno-associated virus (AAV) are commonly found in humans. In seropositive subjects, vector administration is not feasible as antibodies neutralize AAV vectors even at low titers ...
Deschamps, Jack-Yves +17 more
core +1 more source
Glycosylation of recombinant adeno-associated virus serotype 6
Glycosylation of biopharmaceuticals can affect their safety and efficacy. Glycans can occur on recombinant adeno-associated viruses (rAAVs) that are used for gene therapy; however, the types of glycans that attach to rAAVs are controversial.
Yuki Yamaguchi +18 more
doaj +1 more source
Gene Delivery to Nonhuman Primate Preimplantation Embryos Using Recombinant Adeno‐Associated Virus
Delivery of genome editing tools to mammalian zygotes has revolutionized animal modeling. However, the mechanical delivery method to introduce genes and proteins to zygotes remains a challenge for some animal species that are important in biomedical ...
Dan Wang +9 more
doaj +1 more source
Orthopaedic gene therapy using recombinant adeno-associated virus vectors
Use of recombinant adeno-associated virus (rAAV) vectors is increasingly gaining popularity in gene therapy because of their desirable properties, including lack of pathogenicity, efficient transduction of dividing and non-dividing cells, and sustained ...
Ke, J +5 more
core +1 more source
Copyright information:Taken from "Adeno-associated virus (AAV)-mediated suppression of Ca2+/calmodulin kinase IV activity in the nucleus accumbens modulates emotional behaviour in mice"http://www.biomedcentral.com/1471-2202/8/105BMC Neuroscience 2007;8():
Hilmar Bading (78535) +4 more
core +1 more source
Stable Producer Cell Lines for Adeno-Associated Virus (AAV) Assembly
INTRODUCTIONStable producer cell lines containing both the rep and cap genes and recombinant adeno-associated virus (rAAV) vectors can be infected with a helper virus to provide reliable and efficient production of rAAV stocks.
Anna Salvetti, Gilliane Chadeuf
core +1 more source

